الفهرس 
Chapter 1: PsoriasisOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
Psoriasis is a chronic, recurrent, immune-mediated inflammatory skin disease affecting 1-3% of world population and is characterized by epidermal hyperplasia, dilated and prominent blood vessels in the dermis, and an inflammatory infiltrate of leukocytes, predominantly in the dermis.
The genetic, immunological and environmental factors contribute to the pathogenesis of psoriasis, however its exact mechanism remain unknown.
Physical trauma, psychological stress, certain drugs, infections (Streptococcal pharyngitis), metabolic syndrome, and dry weather conditions causing stress on the skin barrier can all precipitate or aggravate the disease by indirectly affecting the internal immunological balance
It is clinically manifested by well-demarcated erythematous plaques with adherent silvery scales. Clinical types include plaque psoriasis, guttate psoriasis, erythrodermic psoriasis, psoriatic arthritis and pustular psoriasis.
Psoriasis vulgaris is the most common variety of psoriasis, representing about 70% to 80% of psoriatic patients.
PASI score is the most widely used tool for assessment of the severity of psoriasis.
Psoriasis is associated with the complex disorder of metabolic syndrome, which incorporates hypertension, dyslipidaemia, obesity, and impaired glucose tolerance. Resistin is a 12 kDa cysteine-rich polypeptide which is produced in humans predominantly by stromal macrophages and monocytes of the visceral adipose tissue. Resistin is known to promote the production of pro-inflammatory mediators involved in the pathogenesis of psoriasis, such as TNF-α and CXCL8.
The aim of the present work was to investigate serum level of resistin in patients with psoriasis compared with healthy controls.
This case control study included 34 subjects, 17 patients with chronic psoriasis and 17 age and gender matched healthy controls. Patients were selected from Dermatology Outpatient clinic, Menoufia University hospitals and Menouf General Hospital, from November 2017 to March 2018. Control subjects were selected from blood bank attendants in Menouf General Hospital.
Exclusion criteria included patients on topical therapy for psoriasis during the last three months prior to the study, patients on systemic therapy and other skin conditions precluding proper assessment of psoriasis severity.
Patients and controls were subjected to complete history taking and clinical and dermatological examination. PASI score was calculated and serum resistin level was measured using human RETN ELISA kit.